Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the Company’s first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category.
Covered in this story
What has happened since
- Syndax Pharmaceuticals Inc is down 0.6% since this was published, 7 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $SNDX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Syndax Pharmaceuticals Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.